clinical trial · NCT07575308
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
Von Willebrand Disease (VWD)Heavy Menstrual Bleeding (HMB)ALN-6400
brief summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
started
May 22, 2026
primary completion
Jun 30, 2027
completion
Nov 29, 2028
last updated
May 14, 2026
official title
HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol